Ambit Biosciences presents study outcomes of its AC220 FLT3 inhibitor for AML Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead item candidate, AC220, in acute myeloid leukemia were presented at the 51st Annual Conference of the American Culture of Hematology in New Orleans. AC220 is a novel, available orally, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 inhibitor for the treatment of AML. The open-label, dose-escalation study, AC220, a Powerful, Selective, Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor, in a First-in-Human Stage I AML Study, was designed to measure the safety, tolerability, and pharmacokinetic profile of AC220 in AML patients with relapsed or refractory disease predominantly http://lepharmaciengiphar.com lepharmaciengiphar.com .
From the description of the video: Shot on the actual roads of SAN FRANCISCO BAY AREA, California, GYM5 features a concentrate on fast, precise and natural driving action. Filmed over four days, director Ben Conrad and his group are back to work on their second Gymkhana production and delivered the entire city of San Francisco as Ken Block’s personal gymkhana playground. Watch the video here:.. Amazing precision generating stunt driver Ken Block demonstrates spectacular mastery in ‘Gymkhana’ video We greatly admire people who have mastered the art of their choice. Be it gymnasts, artists, scientists, mathematicians, poets or martial artists, individuals who achieve greatness within their particular market offer inspiration.